Skip to main content

Fluxion Denies IP Infringement Claims Made by Cellectricon

By a GenomeWeb staff reporter

NEW YORK (Genomeweb News) – Fluxion Biosciences today has denied that it is infringing patents held by Cellectricon that are at the center of an IP infringement suit that initially began in July 2009 but resumed this week.

Cellectricon has claimed that Fluxion is infringing three of its US patents as well as a fourth patent held by Gyros but licensed to Cellectricon. The patents — US Nos. 7,390,650; 7,470,518; 7,563,614; and 5,376,252 — cover microfluidic technology used in Cellectricon's ion channel drug screening solution, the Dynaflow HT System.

In the suit, which was filed in the US District Court for the Northern District of California, Cellectricon claims that Fluxion's IonFlux automated patch clamp system infringes the patents.

Gothenburg, Sweden-based Cellectricon and South San Francisco, Calif.-based Fluxion informed the court on Nov. 23, 2009 that they wished to explore a settlement "within the next 60 days."

However, Cellectricon said earlier this week that it had resumed the litigation.

In response, Fluxion CEO Jeff Jensen said yesterday that the firm would defend the lawsuit vigorously.

"Fluxion has invested considerable time and resources to develop its own intellectual property position for cell-based screening systems, and we respect the intellectual property rights of others," Jensen said. "Cellectricon's claim of patent infringement is a baseless attempt to block Fluxion's penetration and growth in the ion channel screening market."

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.